Published in Health Business Week, November 12th, 2004
Net sales for the third quarter of 2004 are now expected to be approximately $2.8 million, compared with previous guidance of $3.2 million to $3.4 million for the third quarter.
The revision is attributable to lower than expected revenues from the company's copromotion agreement with the Gynecare division of Ethicon, Inc.
The company's net loss guidance for the third quarter is also revised to $6.5 million to $6.8 million, compared with previous net loss guidance of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.